Manni Mohyuddin: My personal preference on T cell redirecting therapy for triple class refractory off trial

Manni Mohyuddin shared a post on X:

“In absence of head to head data, my personal preference on T cell redirecting therapy for triple class refractory off trial:

-slow/indolent relapse: Cilta-cel
-rapid relapse: Elra

Prefer to use talquetamab only after BCMA because it is a very toxic drug that ruins QOL.

Obviously, patient preference reigns supreme. Many will choose bispecifics after hearing the side effects of cilta-cel, which are unpredictable and scary!”

Source: Manni Mohyuddin/X

Dr. Manni Mohyuddin is an Assistant Professor at the Huntsman Cancer Institute, University of Utah, specializing in oncology. He is mainly interested in myeloma, supportive care, end-of-life management, and implementing cost-effective, evidence-based treatment strategies.